Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — 2019 Wells Fargo Healthcare Conference
16 slides from Vivani Medical's conference presentation, Sep 4, 2019
Slide 1: Second Sight Medical Products – 2019 Wells Fargo Healthcare Conference
Second Sight Medical Products, Inc. (NASDAQ: EYES) Discover Life in a New Light® 2019 Wells Fargo Healthcare Conference September 4, 2019 Ex 99.1
Slide 2: Forward Looking Statements
The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" create
Slide 3: Our Mission: To become the standard of care for profound blindness
Our Mission: To become the standard of care for profound blindness The Leader in Neuromodulation for Blindness The first of its kind We are developing the world’s first commercial Visual Cortical Prosthesis Currently in human trials Early feasibility study at Ronald Reagan UCLA Medical Center (UCLA)
Slide 4: The FDA designated Orion as a Breakthrough Device
The FDA designated Orion® as a Breakthrough Device The only FDA designated Breakthrough Device for blindness U.S. human trial initiated in Q1 2018 Platform for continuous innovation and broad commercialization Large potential addressable market with a significant unmet need Directly stimulates the p
Slide 5: Orion Has the Potential to Treat Virtually All Forms of Blindness
Estimated individuals in our potential addressable market in the U.S. Orion ® Has the Potential to Treat Virtually All Forms of Blindness U.S. Market 50,000-100,000 with Light Perception 500,000+ Legally Blind Addressable market Legally blind due to retinitis pigmentosa, glaucoma, diabetic retinopat
Slide 6: Growth Strategy Centered on Orion
Growth Strategy Centered on Orion® Orion Core Competencies Research Execute Orion clinical and R&D programs Positive six- and 12-month results of six subject U.S. Early Feasibility Study at UCLA and Baylor R&D iterating cortical prosthesis and external components in preparation for pivotal clinical
Slide 7: Orion Interim Study Results Support Advancement
Orion® Interim Study Results Support Advancement Ongoing six subject Early Feasibility Study at UCLA Medical Center and Baylor Performance data from feasibility subjects is being used in discussions with FDA to finalize clinical and regulatory pathway in 2019 Initial results from first six subjects*
Slide 8: R&D On-track for Commercial Version
R&D On-track for Commercial Version Changes to the Orion implant are focused on the electronics case to reduce the thickness and improve impact resistance No planned changes to the electrode array design or the materials Improvements to the Orion externals focus on a faster processor and more memory
Slide 9: Research Projects to Enhance User Experience
Research Projects to Enhance User Experience Eye Tracking Move the implant field of view in conjunction with the movement of the user’s eyes Thermal Imaging Infrared imaging would allow users to visualize warm objects such as people in a room Depth-Based Decluttering Allow users to filter out object
Slide 10: Orion Extends our Leadership Position in Artificial Vision
Orion® Extends our Leadership Position in Artificial Vision Established technology with 10+ years proven implant durability Proprietary algorithms for artificial vision Over 85 issued U.S. patents for Orion Orion leverages Argus II technology platform Argus II is an established therapy in over a doz
Slide 11: Pipeline with Clear Path to Innovations
Pipeline with Clear Path to Innovations Argus II: Commercial Orion: Early Feasibility Study Argus 2s: Clinical Validation Study Research CLINICAL TRIALS FDA APPROVAL COMMERCIAL Assistive Technologies Retinitis Pigmentosa Eye Trauma/Injury Glaucoma Diabetic Retinopathy Optic Nerve Disease Enhancement
Slide 12: Experienced Leadership Team
Experienced Leadership Team Will McGuire President & CEO 20+ years experience in medical device industry Extensive leadership experience across both public and private companies Most recently as President of Americas Commercial for Volcano Corporation (acquired by Phillips for $1.2B in 2015). John B
Slide 13: Select Financial Data
Select Financial Data 1) Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation, reserve for excess inventory and inventory impairment charges. (USD $ in thousands) Q2 2019 Q2 2018 Argus® II Implants 11 17 Revenue $1,282 $1,907 Gross Profit $349 $1,071 Net Loss $(8,
Slide 14: Execution on Track in 2019
Execution on Track in 2019 Second Half 2019 Objectives Execute R&D implant and externals projects for commercial version of Orion Finalize agreement with the FDA regarding Orion’s clinical and regulatory path Engage and expand discussions with CMS and private payors while developing a comprehensive
Slide 15: Second Sight Investment Highlights
Second Sight Investment Highlights Orion potentially addresses a significant unmet need for 50,000 to 100,000 individuals in the U.S. Potential to treat nearly all forms of blindness including retinitis pigmentosa, diabetic retinopathy, glaucoma, optic nerve disease and eye injury Six subject feasib
Slide 16: Contacts
Contacts Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 www.secondsight.com Will McGuire President & CEO Direct: 818-833-5040 wmcguire@secondsight.com Institutional Investor Relations Lisa Wilson President In-Site Communications, Inc. Direct
Second Sight Medical Products — 2019 Wells Fargo Healthcare Conference on 6ix